Category Archives: Stem Cell Medicine


Global Stem Cell Therapy Market Growth Factor with Regional Forecast, Segmentation, Investment Opportunities, Industry Research and End User Analysis…

The Stem Cell Therapy Market study describes the current market size and market forecast, market prospects, main drivers and constraints, regulatory scenario, industry trend, PESTLE analysis, PORTER analysis, new product approvals / launch, promotion and marketing campaigns, pricing analysis , competitive environment to assist companies in decision-making. The data from the study is focused on current and historical market dynamics that assist in decisions related to investment.

Stem Cell Therapy offers fundamental industry overview representing market trends, company profiles, growth drivers, market scope and Stem Cell Therapy size estimation. The valuable Stem Cell Therapy industry insights, type, application, deployment status and research regions are studied. A thorough analysis of gross margin view, trade news, industry plans and policies, constraints are explained. A complete Stem Cell Therapy industry scenario is explained from 2014 to 2019 and forecast estimates are presented from 2020-2027. The productions, industry chain analysis, gross margin structure and deployment models are stated in detail. Top regions analysed in the report include North America, South America, Europe, Asia-Pacific, Middle East & Africa and the rest of the world. The Stem Cell Therapy industry presence and maturity analysis will lead to investment feasibility and development scope.

Get A Free Sample Copy Here:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

Stem Cell Therapy Market Leading Players (2019-2027):

Celgene Corporation Osiris Therapeutics, Inc. Pharmicell Co., Ltd MEDIPOST Co., Ltd. Promethera Biosciences Fibrocell Science, Inc. Holostem Terapie Avanzate S.r.l. Cytori Therapeutics Nuvasive, Inc. RTI Surgical, Inc. Anterogen Co., Ltd. RTI Surgical, Inc

Market Segment Analysis

By Types:

Adult Stem Cells Human Embryonic Induced Pluripotent Stem Cells Very Small Embryonic Like Stem Cells

By Applications:

Regenerative Medicine Drug Discovery and Development

By Region

North America

Europe

Asia-Pacific

LAMEA

Ask for Discount @:

https://www.reportspedia.com/discount_inquiry/discount/57925

Stem Cell Therapy Industry Report addresses different regions like North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. The production value, gross margin analysis, development trend, and Stem Cell Therapy market positioning is explained. The industrial chain study, potential buyers, distributors and traders details are explained. The challenges to the growth and market restraints are explained. The market maturity study, investment scope and gross margin study are profiled. The production process structure, market share, manufacturing cost and Stem Cell Therapy saturation analysis is covered. This will helps the industry aspirants to analysis growth feasibility and development plans.

A special highlight on cost structure, import-export scenario and sales channels of Stem Cell Therapy industry is presented. The benchmarking products, dynamic market changes, upstream raw material and downstream buyers analysis are presented. The business trends, key players analysis and product segment study are explained. The regional SWOT analysis, gross margin analysis, application analysis and industry barriers are explained. The value, volume and consumption from 2019-2027 is portrayed. All the essential details like pricing structure of raw materials, labour cost, sales channels and downstream buyers are presented.

Inquire Before Buying Or Ask For Custom Requirement:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

In the next segment, the forecast Stem Cell Therapy industry perspective is covered. Under forecast statistics, the market value, volume and consumption forecast from 2019-2027 is explained. Stem Cell Therapy regional analysis for major regions and countries in this region is stated. The study of new Stem Cell Therapy industry aspirants and analysts opinions for this industry is presented. The limitations to the industry growth, market risks, Stem Cell Therapy growth opportunities and market trends are viewed. The revenue, Stem Cell Therapy market status, past market performance and product details are presented.

Salient Features Of The Report:

The Stem Cell Therapy report serves as a vital guide in portraying present and forecast industry statistics and market size. The supply/ demand situation, gross margin view and competitive profile of top Stem Cell Therapy players are presented. The Stem Cell Therapy market breakdown by product, type, application and regions will provide sophisticated and precise analysis. Recent developments in Stem Cell Therapy industry, growth opportunities, constraints are studied completely. Also, new product launch events, mergers & acquisitions of Stem Cell Therapy, and industry plans and policies are covered.

The revenue estimates of Stem Cell Therapy market based on top industry players, their product type, applications and regions is studied. The cost structures, gross margin view, sales channel analysis and value chain is explained. In the next segment, the SWOT analysis of players, cost structures, traders, distributors and dealers are listed. The forecast study on Stem Cell Therapy industry will be useful for business plans and growth analysis.

To know More Details About Stem Cell Therapy Market research Report @:

https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

Contact Us:

Name: Alex White

Phone: US: +1(806)4400782/ UK: +44 33 3303 4979

Email: [emailprotected]

See the original post:
Global Stem Cell Therapy Market Growth Factor with Regional Forecast, Segmentation, Investment Opportunities, Industry Research and End User Analysis...

Worldwide Regenerative Medicine Industry to 2025 – Featuring Allergan, Amgen and Baxter International Among Others – PRNewswire

DUBLIN, Nov. 9, 2020 /PRNewswire/ -- The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Allergan PLC (AbbVie Inc.), Amgen Inc., Baxter International Inc., BD (Becton, Dickinson and Company), Integra Lifesciences Holdings Corporation, Medtronic plc, Mimedx Group Inc., Novartis AG, Osiris Therapeutics Inc. (Smith & Nephew plc) and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction 4.1 Overview 4.2 Key Industry Trends

5 Global Regenerative Medicine Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast

6 Market Breakup by Type 6.1 Stem Cell Therapy 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Biomaterial 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Tissue Engineering 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Others 6.4.1 Market Trends 6.4.2 Market Forecast

7 Market Breakup by Application 7.1 Bone Graft Substitutes 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Osteoarticular Diseases 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Dermatology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Cardiovascular 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Central Nervous System 7.5.1 Market Trends 7.5.2 Market Forecast 7.6 Others 7.6.1 Market Trends 7.6.2 Market Forecast

8 Market Breakup by End User 8.1 Hospitals 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Specialty Clinics 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Others 8.3.1 Market Trends 8.3.2 Market Forecast

9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast

10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Allergan PLC (AbbVie Inc.) 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Amgen Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Baxter International Inc. 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 BD (Becton, Dickinson and Company) 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis 14.3.5 Integra Lifesciences Holdings Corporation 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.5.4 SWOT Analysis 14.3.6 Medtronic Plc 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Mimedx Group Inc. 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.7.3 Financials 14.3.8 Novartis AG 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Osiris Therapeutics Inc. (Smith & Nephew plc) 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.10 Thermo Fisher Scientific Inc. 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/gcpeaa

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more:
Worldwide Regenerative Medicine Industry to 2025 - Featuring Allergan, Amgen and Baxter International Among Others - PRNewswire

Her favorite part of research was the patients, so she switched to primary… – Bothell-Kenmore Reporter

Dr. Adewunmi Nugas pediatric and internal medicine practice is open to people of all ages, from newborns to geriatrics. Find her at Pacific Medical Centers (PacMed) Canyon Park, 1909 214th St. SE , in Bothell.

Making Bothell healthier by improving access, representation, and mentoring the next generation

Some people live by the adage, if it aint broke, dont fix it. When Dr. Adewunmi (Ade) Nuga looks at the world she asks a different question: could we make this even better?

Dr. Nuga is now a primary care physician at Pacific Medical Centers (PacMed) Canyon Park, but before she went to medical school she earned a PhD in Microbiology and conducted medical research.

One of my research areas was retroviruses, which is the class of virus that HIV belongs to. I wanted to understand why patients with HIV cant stop taking the medications to treat it, even when theyve taken those medications for decades. Where is the virus hiding in the body?

Advances in medications mean patients with HIV can now expect to live an average lifespan, but that wasnt good enough for Dr. Nuga. She hopes her research into bone marrow stem cells will contribute to a cure.

Only two people in the world are confirmed to have been cured of HIV, and both of them received a stem cell transplant as part of their treatment, she says.

Coordinating your care

HIV treatment is not yet part of Dr. Nugas practice, but as a primary care physician she coordinates with specialists and ensures her patients receive comprehensive care for the best possible outcomes. Since people living with HIV can expect to live an average lifespan, they need to continue caring for other aspects of their health in addition to HIV care cancer screenings, mental health, and other ongoing primary care.

Think of Dr. Nuga as your health care quarterback: calling plays and adapting strategies on the fly to develop a treatment plan that works for you. That may mean adjusting doses to your weight and age, but it could also mean adjusting referrals to accommodate your culture, social class or even access to transportation.

I want to address the barriers to care and deliver healthcare to everyone that needs it, regardless of their status. The resources at PacMed are a big help I can coordinate with care managers and community health liaisons to make sure nobody falls through the cracks, she says.

Dr. Nuga loves taking care of patients of all ages, life stages and social situations, and she has a soft spot for children.

Theres a special privilege that comes with taking care of babies from the first day of life, she says, and she hopes to have more opportunities to practice pediatrics.

Another way Dr. Nuga hopes to improve healthcare? Wit better representation throughout the system so patients see themselves in health care professionals from patient care to management.

Im hoping to get involved with the Providence mentorship program, to help inspire the next generation. The number of physicians from some minority groups hasnt changed since 1978 its kind of astounding that over 40 years we havent been able to increase representation, she says. If we improve access to care we make the environment better for everyone.

Dr. Nugas pediatric and internal medicine practice is open to people of all ages, from newborns to geriatrics. Make an appointment with Dr. Nuga for you or your child by calling 425-412-7200 or booking online. Find Dr. Nuga at Pacific Medical Centers (PacMed) Canyon Park, 1909 214th St. SE, in Bothell.

In consideration of how we voice our opinions in the modern world, weve closed comments on our websites. We value the opinions of our readers and we encourage you to keep the conversation going.

Please feel free to share your story tips by emailing editor@bothell-reporter.com.

To share your opinion for publication, submit a letter through our website https://www.bothell-reporter.com/submit-letter/. Include your name, address and daytime phone number. (Well only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 300 words or less, we wont ask you to shorten it.

More here:
Her favorite part of research was the patients, so she switched to primary... - Bothell-Kenmore Reporter

Regenerative Medicine Stem Cells Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019 – KYT24

This report analyzes the current and future prospects of the regenerative medicine across the globe. Regenerative medicine is considered as an emerging field of medical science that aims to regenerate, repair or replace damaged tissue and organs.

The research is a robust combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2015 to 2019, considering the macro and micro environmental factors. Growth rates for each segment within the global regenerative medicine market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

Request a Sample of this Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-1326

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global regenerative medicine market with respect to market segments based on the technology type, application type and geographic analysis.This report includes estimation of theglobal Regenerative Medicine Stem Cells marketin terms of value (USD million) for the period 2015 to 2019. In addition, current trends and recent developments are taken into consideration while determining the growth rate of the global Regenerative Medicine Stem Cells market. The report provides market size and forecast for each segment, sub-segment and geographic region with CAGR % for the period 2015 to 2019.

The global market for regenerative medicine is segmented based on technology as stem cell therapy, biomaterials and tissue engineering. In 2012, biomaterials segment accounted for the largest market share in the global Regenerative Medicine Stem Cells market owing to favorable reimbursement policies and strong demand of biomaterials in the global market. However, high cost associated with biomaterials is a factor that would restrict the global market demand to some extent during the study period.

In addition, based on applications the global market for Regenerative Medicine Stem Cells is segmented as bone graft substitute, osteoarticular diseases, allogeneic bones, autogenic bones and others. In 2012, bone graft substitute segment accounted for the largest market share in the global regenerative medicine bone and joint application market owing to growing demand of bone graft substitute in orthopaedic surgeries. However, post implantation rejection associated with bone graft substitute is considered as a crucial factor that would restrict the global market demand of bone graft substitute.

Geographically, the global Regenerative Medicine Stem Cells market has been segmented into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Market size, forecast and CAGR (%) for each region have been provided. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the Regenerative Medicine Stem Cells market and future opportunities are provided in the report. A PESTLE analysis has also been done while estimating individual geographies in order to provide current as well as future status. A list of recommendations for existing as well as new entrants has also been discussed in the study that is expected to help in decision-making.

Major market players profiled in this report includes Anika Therapeutics, Inc., Arthrex, Inc., Baxter International, Inc., CONMED Corporation, DePuy Synthes, Inc., Medtronic, Inc., Smith & Nephew PLC, Stryker Corporation and Zimmer Holdings, Inc.

Request for Report Ask A Question @https://www.futuremarketinsights.com/ask-question/rep-gb-1326

The global Regenerative Medicine Stem Cells market is segmented as follows:

Excerpt from:
Regenerative Medicine Stem Cells Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2019 - KYT24

How the Election Could Affect Health Care and Drug Policy – Scientific American

With the winner of the presidency and party control of the Senate still unclear the morning after Election Day, the future of the nations health system remains uncertain. At stake is whether the federal government will play a stronger role in financing and setting the ground rules for health care coverage or cede more authority to states and the private sector.

Should President Donald Trump win and Republicans retain control of the Senate, Trump still may not be able to make sweeping changes through legislation as long as the House is still controlled by Democrats. But thanks to rules set up by the Senate GOP the ability to continue to stack the federal courts with conservative jurists who are likely to uphold Trumps expansive use of executive power could effectively remake the governments relationship with the health care system even without signed legislation.

The president has also pledged to continue hisefforts to get rid of the Affordable Care Act, and if the Supreme Court overturns the sweeping law as part of a challenge it will hear next week, the Republicans promise to protect people with preexisting medical conditions will be put to the test. In a second term, the administration would also likely push to continue torevamp Medicaidwith its efforts to institute work requirements for adult enrollees and provide more flexibility for states to change the contours of the program.

If former Vice President Joe Biden wins and Democrats gain a Senate majority, it would represent the first time the party has controlled the White House and both houses of Congress since 2010 the year the ACA was passed. A top priority will be dealing with the COVID-19 pandemic and the economic fallout. Biden made that a keystone of his campaign, promising to implement policies based on advice from medical and scientific advisers and provide more directives and aid to the states.

But also high on his agenda will beaddressing parts of the ACAthat havent worked as well as its authors hoped. He pledged to add a government-run public option, which would be an alternative to private insurance plans on the marketplaces, and to lower the eligibility age for Medicare to 60.

While Democrats will continue to control the House, the final makeup of the Senate is still to be determined. And even if the Democrats win the Senate, they are not expected to come away with a majority that would allow them to pass legislation without support from at least some GOP senators, unless they change the Senates rules. That could lower expectations of what the Democrats can accomplish andmay lead to some tensionsamong members.

But who controls Washington, D.C., is only part of the elections impact on health policy. Several key health issues are on the ballot both directly and indirectly in many states. Here are a few:

In Colorado, a measure that would have banned abortions after 22 weeks of pregnancy except to save the life of the pregnant person failed, according to The Associated Press. Colorado is one of seven states that dont prohibit abortions at some point in pregnancy. It is also home to one of the few clinics in the nation that perform abortions in the third trimester, often for severe medical complications. The clinic drawspatients from around the nation, so residents of other states would have been affected if the Colorado amendment passed.

In Louisiana, however, voters easily approved an amendment to the state constitution to say that nothing in the document protects the right to, or requires the funding of, abortion. That would make it easier for the state to outlaw abortion if the Supreme Court overturnsRoe v. Wade, which makes state abortion bans unconstitutional.

The fate of the Medicaid program, for people with low incomes, was not on the ballot directly anywhere this election. (Voters approved expansions of the program inMissouriandOklahomaearlier this year.) But the program will be affected not only by who controls the presidency and Congress, but also by who controls the legislatures in states that have not expanded the program under the Affordable Care Act.North Carolinais a key swing state where a change in majority in the legislature could turn the expansion tide.

In six states, voters were deciding the legality of marijuana in one form or another. Montana, Arizona and New Jersey were deciding whether to join the 11 states that allow recreational use of the drug. Mississippi and Nebraska voters were choosing whether to legalize medical marijuana, and South Dakota was the first state to vote on legalizing both recreational and medical pot in the same election.

Magic mushrooms were on two ballots. A measure in Oregon to allow the use of psilocybin-producing mushrooms for medicinal purposes passed, and a District of Columbia proposal to decriminalize the hallucinogenic fungi was leading.

Also approved was a separate ballot question in Oregon to decriminalize possession of small amounts of hard drugs, including heroin, cocaine and methamphetamine, and mandate establishing addiction recovery centers, using some tax proceeds from marijuana sales to establish those centers.

As usual, voters in California faced a lengthy list of health-related ballot measures.

For the second time in two years, the states profitable kidney dialysis industry was challenged at the ballot box. Aunion-sponsored initiativewould have required dialysis companies to employ a doctor at every clinic and submit infection reports to the state. But the industry spent $105 million against the measure. It failed, according to AP.

Voters were also asked to decide, again, whether tofund stem cell researchthrough the California Institute for Regenerative Medicine via Proposition 14. Voters first approved funding for the agency in 2004, and since then, billions have been spent with few cures to show for it. The measure was winning in early returns.

California has been at the forefront of the fight over the so-called gig economy, and this years ballot included aproposal pushed by ride-hailing companies like Uber and Lyftthat would let them continue to treat drivers as independent contractors instead of employees. Under Proposition 22, the companies would not have to provide direct health benefits to drivers but would have to give those who qualify a stipend they could use toward a premium for health insurance purchased through the states individual marketplace, Covered California. The measure was approved.

Finally, voters in the Golden State were asked whether toimpose higher property taxeson commercial property owners with land and property holdings valued at $3 million or more, which could help provide new revenue earmarked for economically struggling cities and counties hit hard by COVID-19, as well as K-12 schools and community colleges. Community clinics, California nurses and Planned Parenthood jumped into the thorny political battle over Proposition 15 taking on powerful business groups eyeing revenue to help rebuild Californias underfunded public health system. The measure was too close to call in early returns.

Democrats in California, who control all statewide elected offices and hold a supermajority in the legislature, had been positioning for a Biden win, and some were already penning ambitious health care legislation for next year. Should Biden win, they said, they plan to crack down on hospital consolidation and end surprise emergency room bills, and some were quietly discussing liberal initiatives such as pursuing a single-payer health care system and expanding Medicaid to cover more unauthorized immigrants.

This story was originally published byKaiser Health Newson November 4 2020. Read the original storyhere.

Read more:
How the Election Could Affect Health Care and Drug Policy - Scientific American

A Biden Win and Republican Senate Might Lead to Gridlock on Health Issues – Kaiser Health News

By Julie Rovner November 4, 2020

Former Vice President Joe Biden appeared to be inching toward the 270 electoral votes needed to win the presidency Wednesday afternoon, but at the same time it was becoming clearer that Democrats would not take back the Senate majority they lost in 2014. If that bears out, it could well be a prescription for gridlock on health care.

Without a Democratic majority in the Senate, Biden as president could not likely advance many of his top health agenda items including lowering the eligibility age for Medicare to 60, expanding financial assistance for health insurance under the Affordable Care Act, and creating a public option government health plan.

However, a defeat of President Donald Trump would almost certainly stop his administrations efforts to further erode the effectiveness of the ACA and efforts to turn more of the Medicaid program for those with low incomes back to the states.

Even if Biden wins, this is not the outcome Democrats were hoping for and, to some extent, expecting, based on preelection polling. Andy Slavitt, who ran the Centers for Medicare & Medicaid Services during the Obama administration, noted that frustration in a tweet Wednesday. A large disappointment is that many hoped for a significant repudiation of Trump & his indifference to human life, human suffering, his corruption, and goal of getting rid of the ACA. No matter the final total it will be hard to make that claim, Slavitt said.

Still up in the air is how willing a Republican-led Senate will be to provide further relief to individuals, businesses and states hit hard by the coronavirus epidemic, and whether they will participate in previously bipartisan efforts to curtail surprise out-of-network medical bills and get a handle on prescription drug prices.

To be sure, nothing is final as several key swing states, including Pennsylvania, are still counting thousands of mail-in and early votes. But by midafternoon, Biden was projected by news outlets to have won 253 electoral votes, while Trump had 214. Unofficial returns also showed Biden leading in several states, including Arizona and Nevada, and close to the president in Georgia, where early ballots were still being counted.

Biden was quick to note that nothing is final in brief remarks he made Wednesday afternoon. Im not here to declare that weve won, he said, but I am here to declare that, when the count is finished, we believe that we will be the winners.

Although Democrats poured tens of millions of dollars into races to defeat vulnerable Republican senators this year, most of the incumbents including Sens. Susan Collins (Maine), Steve Daines (Montana), Joni Ernst (Iowa) and Lindsey Graham (South Carolina) won their battles. Several races are still too close to call.

But who controls Washington, D.C., is only part of the elections impact on health policy. Several key health issues were on the ballot both directly and indirectly in many states. Here are a few:

Abortion

In Colorado, a measure that would have banned abortions after 22 weeks of pregnancy except to save the life of the pregnant person failed, according to The Associated Press. Colorado is one of seven states that dont prohibit abortions at some point in pregnancy. It is also home to one of the few clinics in the nation that perform abortions in the third trimester, often for severe medical complications. The clinic draws patients from around the nation, so residents of other states would have been affected if the Colorado amendment had passed.

In Louisiana, however, voters easily approved an amendment to the state constitution to say that nothing in the document protects the right to, or requires the funding of, abortion. That would make it easier for the state to outlaw abortion if the Supreme Court overturns Roe v. Wade, which makes state abortion bans unconstitutional.

Medicaid

The fate of the Medicaid program, for people with low incomes, was not on the ballot directly anywhere this election. (Voters approved expansions of the program in Missouri and Oklahoma earlier this year.) But the program will be affected not only by who controls the presidency and Congress, but also by who controls the legislatures in states that have not expanded the program under the Affordable Care Act. North Carolina is a key swing state where a change in majority in the legislature could have turned the expansion tide, but Republicans held onto their majority.

Drug Policy

In six states, voters were deciding the legality of marijuana in one form or another. Montana, Arizona and New Jersey opted to join the 11 states that allow recreational use of the drug. Mississippi voters agreed to legalize medical marijuana, and South Dakota approved legalizing both recreational and medical pot.

Magic mushrooms were on two ballots. A measure in Oregon to allow the use of psilocybin-producing mushrooms for medicinal purposes passed, as did a District of Columbia proposal to decriminalize the hallucinogenic fungi.

Also approved was a separate ballot question in Oregon to decriminalize possession of small amounts of hard drugs, including heroin, cocaine and methamphetamine, and mandate establishing addiction recovery centers, using some tax proceeds from marijuana sales to establish those centers.

California

As usual, voters in California faced a lengthy list of health-related ballot measures.

For the second time in two years, the states profitable kidney dialysis industry was challenged at the ballot box. A union-sponsored initiative would have required dialysis companies to employ a doctor at every clinic and submit infection reports to the state. But the industry spent $105 million against the measure. It failed, according to unofficial returns posted by the state.

Voters were also asked to decide, again, whether to fund stem cell research through the California Institute for Regenerative Medicine via Proposition 14. Voters first approved funding for the agency in 2004, and since then, billions have been spent with few cures to show for it. The measure passed.

California has been at the forefront of the fight over the so-called gig economy, and this years ballot included a proposal pushed by ride-hailing companies like Uber and Lyft that would let them continue to treat drivers as independent contractors instead of employees. Under Proposition 22, the companies would not have to provide direct health benefits to drivers but would have to give those who qualify a stipend they could use toward a premium for health insurance purchased through the states individual marketplace, Covered California. The measure was approved.

Finally, voters in the Golden State were asked whether to impose higher property taxes on commercial property owners with land and property holdings valued at $3 million or more, which could help provide new revenue earmarked for economically struggling cities and counties hit hard by COVID-19, as well as K-12 schools and community colleges. Community clinics, California nurses and Planned Parenthood jumped into the thorny political battle over Proposition 15 taking on powerful business groups eyeing revenue to help rebuild Californias underfunded public health system. The measure appeared to have failed in a close vote.

Democrats in California, who control all statewide elected offices and hold a supermajority in the legislature, had been positioning for a Biden win, and some were already penning ambitious health care legislation for next year. Should Biden win, they said, they plan to crack down on hospital consolidation and end surprise emergency room bills, and some were quietly discussing liberal initiatives such as pursuing a single-payer health care system and expanding Medicaid to cover more unauthorized immigrants.

JoNel Aleccia, Rachel Bluth, Angela Hart, Matt Volz and Samantha Young contributed to this story.

Kaiser Health News (KHN) is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation which is not affiliated with Kaiser Permanente.

This story can be republished for free (details).

We encourage organizations to republish our content, free of charge. Heres what we ask:

You must credit us as the original publisher, with a hyperlink to our khn.org site. If possible, please include the original author(s) and Kaiser Health News in the byline. Please preserve the hyperlinks in the story.

Its important to note, not everything on khn.org is available for republishing. If a story is labeled All Rights Reserved, we cannot grant permission to republish that item.

Have questions? Let us know at KHNHelp@kff.org

The rest is here:
A Biden Win and Republican Senate Might Lead to Gridlock on Health Issues - Kaiser Health News

Angelika Amon, cell biologist who pioneered research on chromosome imbalance, dies at 53 – MIT News

Angelika Amon, professor of biology and a member of the Koch Institute for Integrative Cancer Research, died on Oct. 29 at age 53, following a two-and-a-half-year battle with ovarian cancer.

"Known for her piercing scientific insight and infectious enthusiasm for the deepest questions of science, Professor Amon built an extraordinary career and in the process, a devoted community of colleagues, students and friends," MIT President L. Rafael Reif wrote in a letter to the MIT community.

Angelika was a force of nature and a highly valued member of our community, reflects Tyler Jacks, the David H. Koch Professor of Biology at MIT and director of the Koch Institute. Her intellect and wit were equally sharp, and she brought unmatched passion to everything she did. Through her groundbreaking research, her mentorship of so many, her teaching, and a host of other contributions, Angelika has made an incredible impact on the world one that will last long into the future.

A pioneer in cell biology

From the earliest stages of her career, Amon made profound contributions to our understanding of the fundamental biology of the cell, deciphering the regulatory networks that govern cell division and proliferation in yeast, mice, and mammalian organoids, and shedding light on the causes of chromosome mis-segregation and its consequences for human diseases.

Human cells have 23 pairs of chromosomes, but as they divide they can make errors that lead to too many or too few chromosomes, resulting in aneuploidy. Amons meticulous and rigorous experiments, first in yeast and then in mammalian cells, helped to uncover the biological consequences of having too many chromosomes. Her studies determined that extra chromosomes significantly impact the composition of the cell, causing stress in important processes such as protein folding and metabolism, and leading to additional mistakes that could drive cancer. Although stress resulting from aneuploidy affects cells ability to survive and proliferate, cancer cells which are nearly universally aneuploid can grow uncontrollably. Amon showed that aneuploidy disrupts cells usual error-repair systems, allowing genetic mutations to quickly accumulate.

Aneuploidy is usually fatal, but in some instances extra copies of specific chromosomes can lead to conditions such as Down syndrome and developmental disorders including those known as Patau and Edwards syndromes. This led Amon to work to understand how these negative effects result in some of the health problems associated specifically with Down syndrome, such as acute lymphoblastic leukemia. Her expertise in this area led her to be named co-director of the recently established Alana Down Syndrome Center at MIT.

Angelikas intellect and research were as astonishing as her bravery and her spirit. Her labs fundamental work on aneuploidy was integral to our establishment of the center, say Li-Huei Tsai, the Picower Professor of Neuroscience and co-director of the Alana Down Syndrome Center. Her exploration of the myriad consequences of aneuploidy for human health was vitally important and will continue to guide scientific and medical research.

Another major focus of research in the Amon lab has been on the relationship between how cells grow, divide, and age. Among other insights, this work has revealed that once cells reach a certain large size, they lose the ability to proliferate and are unable to reenter the cell cycle. Further, this growth contributes to senescence, an irreversible cell cycle arrest, and tissue aging. In related work, Amon has investigated the relationships between stem cell size, stem cell function, and tissue age. Her labs studies have found that in hematopoetic stem cells, small size is important to cells ability to function and proliferate in fact, she posted recent findings on bioRxiv earlier this week and have been examining the same questions in epithelial cells as well.

Amon lab experiments delved deep into the mechanics of the biology, trying to understand the mechanisms behind their observations. To support this work, she established research collaborations to leverage approaches and technologies developed by her colleagues at the Koch Institute, including sophisticated intestinal organoid and mouse models developed by the Yilmaz Laboratory, and a microfluidic device developed by the Manalis Laboratory for measuring physical characteristics of single cells.

The thrill of discovery

Born in 1967, Amon grew up in Vienna, Austria, in a family of six. Playing outside all day with her three younger siblings, she developed an early love of biology and animals. She could not remember a time when she was not interested in biology, initially wanting to become a zoologist. But in high school, she saw an old black-and-white film from the 1950s about chromosome segregation, and found the moment that the sister chromatids split apart breathtaking. She knew then that she wanted to study the inner workings of the cell and decided to focus on genetics at the University of Vienna in Austria.

After receiving her BS, Amon continued her doctoral work there under Professor Kim Nasmyth at the Research Institute of Molecular Pathology, earning her PhD in 1993. From the outset, she made important contributions to the field of cell cycle dynamics. Her work on yeast genetics in the Nasmyth laboratory led to major discoveries about how one stage of the cell cycle sets up for the next, revealing that cyclins, proteins that accumulate within cells as they enter mitosis, must be broken down before cells pass from mitosis to G1, a period of cell growth.

Towards the end of her doctorate, Amon became interested in fruitfly genetics and read the work of Ruth Lehmann, then a faculty member at MIT and a member of the Whitehead Institute. Impressed by the elegance of Lehmanns genetic approach, she applied and was accepted to her lab. In 1994, Amon arrived in the United States, not knowing that it would become her permanent home or that she would eventually become a professor.

While Amons love affair with fruitfly genetics would prove short, her promise was immediately apparent to Lehmann, now director of the Whitehead Institute. I will never forget picking Angelika up from the airport when she was flying in from Vienna to join my lab. Despite the long trip, she was just so full of energy, ready to talk science, says Lehmann. She had read all the papers in the new field and cut through the results to hit equally on the main points.

But as Amon frequently was fond of saying, yeast will spoil you. Lehmann explains that because they grow so fast and there are so many tools, your brain is the only limitation. I tried to convince her of the beauty and advantages of my slower-growing favorite organism. But in the end, yeast won and Angelika went on to establish a remarkable body of work, starting with her many contributions to how cells divide and more recently to discover a cellular aneuploidy program.

In 1996, after Lehmann had left for New York Universitys Skirball Institute, Amon was invited to become a Whitehead Fellow, a prestigious program that offers recent PhDs resources and mentorship to undertake their own investigations. Her work on the question of how yeast cells progress through the cell cycle and partition their chromosomes would be instrumental in establishing her as one of the worlds leading geneticists. While at Whitehead, her lab made key findings centered around the role of an enzyme called Cdc14 in prompting cells to exit mitosis, including that the enzyme is sequestered in a cellular compartment called the nucleolus and must be released before the cell can exit.

I was one of those blessed to share with her a eureka moment, as she would call it, says Rosella Visintin, a postdoc in Amons lab at the time of the discovery and now an assistant professor at the European School of Molecular Medicine in Milan. She had so many. Most of us are lucky to get just one, and I was one of the lucky ones. Ill never forget her smile and scream neither will the entire Whitehead Institute when she saw for the first time Cdc14 localization: You did it, you did it, you figured it out! Passion, excitement, joy everything was in that scream.

In 1999, Amons work as a Whitehead Fellow earned her a faculty position in the MIT Department of Biology and the MIT Center for Cancer Research, the predecessor to the Koch Institute. A full professor since 2007, she also became the Kathleen and Curtis Marble Professor in Cancer Research, associate director of the Paul F. Glenn Center for Biology of Aging Research at MIT, a member of the Ludwig Center for Molecular Oncology at MIT, and an investigator of the Howard Hughes Medical Institute.

Her pathbreaking research was recognized by several awards and honors, including the 2003 National Science Foundation Alan T. Waterman Award, the 2007 Paul Marks Prize for Cancer Research, the 2008 National Academy of Sciences (NAS) Award in Molecular Biology, and the 2013 Ernst Jung Prize for Medicine. In 2019, she won the Breakthrough Prize in Life Sciences and the Vilcek Prize in Biomedical Science, and was named to the Carnegie Corporation of New Yorks annual list of Great Immigrants, Great Americans. This year, she was given the Human Frontier Science Program Nakasone Award. She was also a member of the NAS and the American Academy of Arts and Sciences.

Lighting the way forward

Amons perseverance, deep curiosity, and enthusiasm for discovery served her well in her roles as teacher, mentor, and colleague. She has worked with many labs across the world and developed a deep network of scientific collaboration and friendships. She was a sought-after speaker for seminars and the many conferences she attended. In over 20 years as a professor at MIT, she has mentored more than 80 postdocs, graduate students, and undergraduates, and received the School of Sciences undergraduate teaching prize.

Angelika was an amazing, energetic, passionate, and creative scientist, an outstanding mentor to many, and an excellent teacher, says Alan Grossman, the Praecis Professor of Biology and head of MITs Department of Biology. Her impact and legacy will live on and be perpetuated by all those she touched.

Angelika existed in a league of her own, explains Kristin Knouse, one of Amons former graduate students and a current Whitehead Fellow. She had the energy and excitement of someone who picked up a pipette for the first time, but the brilliance and wisdom of someone who had been doing it for decades. Her infectious energy and brilliant mind were matched by a boundless heart and tenacious grit. She could glance at any data and immediately deliver a sharp insight that would never have crossed any other mind. Her positive attributes were infectious, and any interaction with her, no matter how transient, assuredly left you feeling better about yourself and your science.

Taking great delight in helping young scientists find their own eureka moments, Amon was a fearless advocate for science and the rights of women and minorities and inspired others to fight as well. She was not afraid to speak out in support of the research and causes she believed strongly in. She was a role model for young female scientists and spent countless hours mentoring and guiding them in a male-dominated field. While she graciously accepted awards for women in science, including the Vanderbilt Prize and the Women in Cell Biology Senior Award, she questioned the value of prizes focused on women as women, rather than on their scientific contributions.

Angelika Amon was an inspiring leader, notes Lehmann, not only by her trailblazing science but also by her fearlessness to call out sexism and other -isms in our community. Her captivating laugh and unwavering mentorship and guidance will be missed by students and faculty alike. MIT and the science community have lost an exemplary leader, mentor, friend, and mensch.

Amons wide-ranging curiosity led her to consider new ideas beyond her own field. In recent years, she has developed a love for dinosaurs and fossils, and often mentioned that she would like to study terraforming, which she considered essential for a human success to life on other planets.

It was always amazing to talk with Angelika about science, because her interests were so deep and so broad, her intellect so sharp, and her enthusiasm so infectious, remembers Vivian Siegel, a lecturer in the Department of Biology and friend since Amons postdoctoral days. Beyond her own work in the lab, she was fascinated by so many things, including dinosaurs dreaming of taking her daughters on a dig lichen, and even life on Mars.

Angelika was brilliant; she illuminated science and scientists, says Frank Solomon, professor of biology and member of the Koch Institute. And she was intense; she warmed the people around her, and expanded what it means to be a friend.

Amon is survived by her husband Johannes Weis, and her daughters Theresa and Clara Weis, and her three siblings and their families.

View original post here:
Angelika Amon, cell biologist who pioneered research on chromosome imbalance, dies at 53 - MIT News

USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife – USC Dornsife College of Letters, Arts and…

Provost Professor Scott Fraser is recognized for developing technology that provides unprecedented views of live organisms, from embryonic development to old age. [3 min read]

Provost Professor Scott Fraser, a recognized innovator whose inventions have found wide use in both scientific and clinical settings, is an elected member of the National Academy of Medicine. (Photo: No Montes.)

Scott Fraser, Provost Professor of Biological Sciences, Biomedical Engineering, Physiology and Biophysics, Stem Cell Biology and Regenerative Medicine, Pediatrics, Radiology and Ophthalmology, has been elected to the National Academy of Medicine.

Fraser, who holds joint appointments at the USC Dornsife College of Letters, Arts and Sciences and USC Viterbi School of Engineering as well as the Elizabeth Garrett Chair in Convergent Bioscience, is one of just 90 researchers chosen from among the worlds leading scientists to become members of the academy.

Professor Scott E. Fraser is a brilliant biophysicist and innovator, said USC Provost Charles F. Zukoski. He is being recognized for groundbreaking advancements in biology and medicine. His research, which centers on imaging and molecular analyses of intact biological systems, serves as inspiration for future generations of engineers, scientists and medical professionals.

Among the reasons for his election, the academy noted Frasers work integrating biophysics, quantitative biology, and molecular imaging to enable unprecedented views of normal function and disease in live organisms, from embryonic development to old age.

Ive always been fascinated by interdisciplinary teams that can bring new insights into old problems by combining the insights from science, engineering and medicine, Fraser said.

Applying tricks from other fields

Fraser, who earned his bachelors degree in physics and his Ph.D. in biophysics, says he gravitated toward research in biology because there are so many open questions, and so many things that have been thought to be impossible to answer but tricks from other fields make the impossible possible, if the team is willing to tackle it together.

Frasers research delves into early development, organogenesis (the process by which internal organs emerge and develop) and medical diagnostics. His work has spawned several start-up companies and has been used in a number of instruments and FDA-approved diagnostics.

We keep our eyes open to translation of the work in the lab to industrial and clinical utility, he said, adding that USCs Alfred E. Mann Institute for Biomedical Engineering and USC Viterbis National Science Foundation-funded Innovation Corps node have both played key roles and offered important instruction on how to best bring their work to potential customers.

In the last year, our IP (intellectual property) has been licensed by a half-dozen different companies, he said. So, we know the work can lead to new instruments, new diagnostics and new techniques.

Fraser said his team works diligently to ensure collaborators in scientific and clinical fields also benefit from their efforts.

We have built the Translational Imaging Center on the University Park campus and the Translational Biomedical Imaging Center at Childrens Hospital Los Angeles to help support users with interests in fields ranging from regenerative medicine to cancer and diabetes. This is already empowering them to make new insights into their research challenges.

What we hope to do is to make it possible for researchers and clinicians to have aha moments, when they can see things for the first time.

A career highlighted by innovation

After earning his Ph.D. in 1979, Fraser joined the faculty at the University of California, Irvine, where he rose through the ranks to become chair of the Department of Physiology and Biophysics. In 1990, he moved to Caltech to serve as the Anna L. Rosen Professor of Biology and the director of the Biological Imaging Center. There, he served as the founding director of both the Caltech Brain Imaging Center and the Rosen Center for Biological Engineering and helped found the Kavli Nanoscience Institute.

In Fall 2012, Fraser moved to USC as Provost Professor at USC Dornsife and USC Viterbi, with formal links to Childrens Hospital Los Angeles and Keck School of Medicine of USC. He serves as the director of science initiatives for USC as well as co-director of the Bridge Institute at the USC Michelson Center for Convergent Bioscience.

A prolific author and inventor, Fraser has more than 240 peer-reviewed articles and more than 75 issued patents to his credit. He is the recipient of numerous honors and has been elected to the National Academy of Inventors, the American Institute for Medical and Biological Engineering, the American Association for the Advancement of Science, the American Academy of Arts and Sciences and the European Academy of Science.

About the National Academy of Medicine

The National Academy of Medicine, established in 1970 as the Institute of Medicine, is an independent organization of professionals from diverse fields including health and medicine, and the natural, social and behavioral sciences. Election to the academy recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

See the original post:
USC biological imaging innovator elected to National Academy of Medicine > News > USC Dornsife - USC Dornsife College of Letters, Arts and...

Repurposing and Combining Drugs An Effective Cancer Treatment Strategy – Technology Networks

Read Time:

Dr Robert Nagourneyis the founder and medical director of Nagourney Cancer Institute, and clinical professor at the University of California, Irvine School of Medicine. Nagourney is having success investigating whether a unique combination of existing and approved cancer drugs might be more effective compared to off-the-shelf treatments. Technology Networks recently had the pleasure of speaking with Nagourney to learn more about his work focused on repurposing drugs. He discusses the challenges and benefits of exploring new uses for drugs that are outside the scope of their original indication. He also shares a case whereby a cancer patient was recently treated with a tailored drug combination and explains how it was possible to design an effective personalized treatment strategy. Laura Lansdowne (LL): Can you touch on the importance of physiological relevance when testing therapeutics inin vitrosystems, has there been any key advances in cell culture technologies that have been particularly effective at improving this? Robert Nagourney (RN): The wide use of genomic profiling by next-generation sequencing (NGS) has provided targetable mutations in a number of cancers including chronic myeloid leukemia (CML), several forms of lung cancer, kidney cancersand melanoma. However, the majority of human tumors do not reveal actionable mutations. Today these tumors are treated with cytotoxic chemotherapy or experimental drugs with no attempt to select among options and offer combinations that are patient specific. To address patients needs we developed the Ex Vivo Analysis of Programmed Cell Death or EVA/PCD platform. Two fundamental advances have led to the successful application of our EVA/PCD technology for the prediction of patient response over older technologies.

LL: Could you tell us more about your work repurposing drugs? RN: Drugs do not know what diseases they were invented for. This not only applies to drugs for cancer but to other drugs with biological effect that can influence cancer cell behavior. LL: In yourblogyoushare the story of a Stage 4 gastroesophageal cancer patient that was recently treated with a tailored drug combination. Could you elaborate on the genetic clue that helped design an effective combination therapy? RN: The patient was found sensitive to a drug that targets EGFR a cell signaling pathway. However,he did not have a mutation in EGFR. As such his doctors did not anticipate a likelihood of benefit from drugs that target EGFR and did not offer him these agents. In our EVA/PCD we found activity for these drugs. When we reviewed his gene profile it showed an EGFR amplification (not a mutation). Since EGFR amplificationis not considered a target, no drug was offered but with thediscriminating (functional) capability of the EVA/PCD assay, he indeed was that rare person with an EGFR amplification who would actually likely respond and when we gave it to him he did Completely! LL: When repurposing a drug, how careful do we need to be when considering existing safety and efficacy data? E.g. data that were obtained in previous studies, fordifferentindications, in adifferentstudy population (age/sex/ethnicity, etc.). RN: Any novel combination runs some risk, but many repurposed drugs are already in wide use, and very often are used in combination with many other drugs. I am not a proponent of random combinations (however many commercial firms do offer them) but instead like to examine the patient's likelihood of benefit when we do suggest a drug or combination. LL: What measures/approaches should be taken when considering off-label use of a drug? RN: Usually these drugs are well known for their modes of action and toxicity. The literature provides ample information on drugdrug interactions and usually can be consulted if an unusual combination is being considered. LL: There is currently no regulatory requirement to know the molecular target of a drug, as long the drug is shown to be safe and efficacious. How much of a drawback does this gap in knowledge present, in terms of repurposing existing drugs for other indications? RN: Actually, many new drugs come with companion diagnostics. That is, you can only get a TRK inhibitor if you are shown to carry and NTRK fusion. Where functional platforms can be immensely helpful is the vast amount of genomic regulation and cellular gene activity that cannot be identified at a genetic level.One perfect example in the oncogene MYC. This super-regulator that functions epigenetically is abnormally active in up to 70% of cancers, it regulates over 3600 individual human genes (15% of the human genome) and isalmost never mutated ever. Thus, it is only by probing its activities at a functional level that you know to target it therapeutically. Gene profiles are useless. Robert Nagourney was speaking with Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks. Interviewee Biography Dr Nagourney is a native of Connecticut and a graduate of McGill University School of Medicine and became disenchanted with the trial and error approach that he witnessed during fellowships at Georgetown and The Scripps Institute.Nagourney is currently a practicing oncologist and triple board certified in Internal Medicine, Medical Oncology and Hematology. Among his many accomplishments, as co-investigator on national cooperative trials. He is recognized for the introduction of Cisplatin/Gemcitabine doublets in the treatment of advanced ovarian and breast cancers. With more than 20 years of experience in human tumor primary culture analyses, Dr Nagourney has authored more than 100 manuscripts, book chapters and abstracts including publications in the Journal of Clinical Oncology, Gynecologic Oncology, the Journal of the National Cancer Institute and British Journal of Cancer.

Follow this link:
Repurposing and Combining Drugs An Effective Cancer Treatment Strategy - Technology Networks

Rates of Invasive Pulmonary Aspergillosis in ICU Patients With Influenza Far Lower Than Previously Thought – Contagionlive.com

Despite recent studies identifying invasive pulmonary aspergillosis (IPA) as a common complication of severe influenza, even in hosts who are immunocompetent, a retrospective look at the last 9 influenza seasons at 1 healthcare center in the United States tells a different tale.

In a poster presented virtually at ID Week 2020, investigators at Northwestern Universitys Feinberg School of Medicine determined the incidence of IPA among critically ill patients with influenza over multiple seasons and sought to track outcomes and hone in on predisposing risk factors.

Data were collected at a single healthcare center in Chicago, Illinois, across 9 influenza seasons (March 2009 March 2018), and included patients > age 18 who were admitted to the intensive care unit (ICU) with respiratory distress and had a positive influenza polymerase chain reaction test.

Investigators relied on criteria from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) to define IPA, as well as the revised AspICUcriteria.

The study population comprised 224 patients admitted to the ICU with influenza, and the overall rate of IPA was 3.1% (7/224). History of stem cell transplant was found to be a statistically significant risk factor for IPA (P = .015), with hematologic malignancy (P = .09), lung disease (P = .098), and obesity (P = .051) tending toward significance. Only 1 out of 7 patients with IPA was not immunosuppressed.

Length of hospital stay was significantly increased for patients with IPA (P = .046), but there was no significant difference in need for mechanical ventilation, renal replacement therapy, or death in these patients.

Other coinfections were common in these patients, with 31.3% bacterial, 7.6% viral, and 8.9% non-aspergillosis fungi infections reported.

The incidence of IPA was significantly lower (3.1%) in our study over 9 influenza seasons than has been reported in similar studies, investigators concluded. History of stem cell transplant was a risk factor strongly associated with the development of IPA. IPA did not significantly predict morbidity and mortality among critically ill influenza patients.

The poster, Aspergillosis Complicating Severe Influenza in ICU Patients: A Retrospective Cohort Study, was presented virtually at ID Week 2020.

Read the original:
Rates of Invasive Pulmonary Aspergillosis in ICU Patients With Influenza Far Lower Than Previously Thought - Contagionlive.com